{
  "id": "law--intellectual-property--t-pharmaceutical-patents-and-generic-drugs",
  "version": 1,
  "subject": "Law",
  "subcategory": "Intellectual Property Law",
  "course_id": "law--intellectual-property",
  "chapter_id": "law--intellectual-property--ch02-patents",
  "title": "Pharmaceutical Patents and Generic Drugs",
  "emoji": "ğŸ’¡",
  "color": "#D4AC0D",
  "description": "A 1-minute de-risking session on Pharmaceutical Patents and Generic Drugs.",
  "is_free": false,
  "published": true,
  "story": {
    "hook": {
      "text": "A life-saving drug costs $10,000 a month. The patent expires and the generic version costs $50. Same drug.",
      "visual": "ğŸ’Š"
    },
    "buildup": {
      "text": "Pharmaceutical companies patent new drugs, giving them exclusive rights to sell for 20 years from filing.",
      "visual": "ğŸ“œ"
    },
    "discovery": {
      "text": "High prices during the patent period fund researchâ€”developing a new drug costs an average of $2.6 billion.",
      "visual": "ğŸ’¸"
    },
    "twist": {
      "text": "Companies use 'evergreening'â€”filing new patents on minor changesâ€”to extend monopolies beyond the original term.",
      "visual": "ğŸ”„"
    },
    "climax": {
      "text": "The Hatch-Waxman Act balances innovation and access by streamlining generic drug approval after patents expire.",
      "visual": "âš–ï¸"
    },
    "punchline": {
      "text": "Patents fund research. Generics fund access. The tension is permanent.",
      "visual": "ğŸ’Š"
    }
  },
  "quiz": {
    "question": "What is 'evergreening' in pharmaceutical patents?",
    "options": [
      "Making drugs from plants",
      "Filing new patents on minor changes to extend monopolies",
      "Reducing drug prices over time"
    ],
    "correct": 1
  }
}
